Clinical Trial

Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)

Study acronym: Diabetes-CV
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The Diabetes-CV study is an observational study designed to assess the prognostic value of serum cardiac damage markers high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic peptide (NT-proBNP), and soluble suppression of tumorigenesis-2 (sST2) in predicting mortality, major adverse cardiovascular events, and diabetic complications in patients with type 2 diabetes.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-24; most recent amendment 2026-06-10.
Status change: Recruiting → Active, Not Recruiting 2026-06-10
Trial Details
NCT Number NCT06902857
Lead Sponsor Istituto Nazionale di Ricovero e Cura per Anziani
Conditions Type 2 Diabetes, Cardiovascular Complication
Enrollment 964 participants
Start Date 2024-04-18
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-12